Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Mar 2;42(1):113.
doi: 10.1007/s00345-024-04799-4.

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

Naoki Wada  1 , Mitsuhiro Mizunaga  2 , Noriyuki Abe  3 , Kotona Miyauchi  3 , Shin Kobayashi  3 , Miyu Ohtani  3 , Ryoken Tsunekawa  3 , Masaya Nagabuchi  3 , Shun Morishita  3 , Teppei Ohyama  4 , Satoshi Yamaguchi  4 , Hiromichi Iuchi  5 , Tsuyoshi Noda  6 , Yuji Saga  6 , Tadasu Motoya  7 , Norihiro Kawakami  7 , Masayuki Nishihara  8 , Atsushi Numata  9 , Hidehiro Kakizaki  3
Affiliations
Randomized Controlled Trial

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

Naoki Wada et al. World J Urol. .

Abstract

Purpose: To compare the efficacy and safety of mirabegron and vibegron in female OAB patients.

Methods: We conducted a multicenter, prospective, randomized crossover study of female patients with OAB. The patients were assigned to Group MV (mirabegron for 8 weeks, followed by vibegron for 8 weeks) or group VM (vibegron for 8 weeks, followed by mirabegron for 8 weeks). The primary endpoint was the change in OABSS from baseline, and the secondary endpoint was the change in FVC parameters. After completion of the study, each patient was asked which drug was preferable.

Results: A total of 83 patients were enrolled (40 and 43 in groups MV and VM, respectively). At 8th and 16th week, 33 and 29 in Group MV and 34 and 27 in Group VM continued to receive the treatment. The change in PVR was not significantly different between treatment with mirabegron and vibegron. The changes in OABSS, nighttime frequency, mean, and maximum voided volume were similar between mirabegron and vibegron. The mean change in the daytime frequency was greater in the vibegron than in the mirabegron. Of the 56 patients, 15 (27%) and 30 (53%) preferred mirabegron and vibegron, respectively. The remaining 11 patients (20%) showed no preference. The change in the urgency incontinence score during vibegron was better in patients who preferred vibegron to mirabegron.

Conclusion: The efficacies of mirabegron and vibegron in female patients was similar. The patients' preference for vibegron could depend on the efficacy of vibegron for urgency incontinence.

Keywords: Mirabegron; Overactive bladder; Randomized study; Vibegron.

PubMed Disclaimer

Comment in

References

    1. Reynolds WS, Fowke J, Dmochowski R (2016) The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep 11:8–13 - DOI - PubMed - PMC
    1. Homma Y, Yamaguchi O, Hayashi K et al (2005) An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 96:1314–1318 - DOI - PubMed
    1. Zillioux J, Welk B, Suskind AM et al (2022) SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn 41:1928–1933 - DOI - PubMed
    1. Yamaguchi O (2002) β3-adrenoceptors in human detrusor muscle. Urology 59:25–29 - DOI - PubMed
    1. Nomiya M, Yamaguchi O (2003) A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170:649–653 - DOI - PubMed

Publication types

Substances

LinkOut - more resources